Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

Zhao, Yingxin; Wang, Yongjian; Lou, Han-Yu; Shan, Peng-Fei

doi:10.18632/oncotarget.17515

Cited by 27 publications

(20 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several systematic reviews and meta-analyses on diabetes medication use and cancer risk association have been published (33)(34)(35)(36)(37)(38)(39)(40). But previous reviews did not investigate proposed cancer sites (33) or only evaluated associations with well-established medications (34,(36)(37)(38)(39)(40). Based on recent evidence, this systematic review will evaluate the role of various diabetes medications in site-speci c cancers (breast, lung, colorectal, prostate, liver, and pancreatic cancers).…”

Section: Discussionmentioning

confidence: 99%

Diabetes Medication Use and Cancer Risk: Protocol for a Systematic Review

Chen¹,

Mushashi²,

Son³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Cancer is a growing public health challenge. Innovative approaches to prevent the future burden of cancer are needed. Diabetes medications may help to decrease the risk of cancers, however, a better understanding of relationships by cancer site and diabetes medication class are essential to guide future clinical trials. However, there is not adequate knowledge synthesis on different types of diabetes medications and cancer types. We aim to provide an integrated view of diabetes medications’ role and site-specific cancers.Methods: This systematic review will include observational studies (cohort, nested case-control, case-cohort, and case-control) and randomized controlled trials in human adults in which the effect of diabetes medication use on breast, lung, colorectal, prostate, liver, and pancreatic cancers was evaluated. The former four are among the most common cancer types, while liver and pancreatic cancer are of interest due to the biological roles of the liver and pancreas in blood glucose regulation. MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL will be searched using a comprehensive and sensitive search strategy. The reference list of identified studies and relevant systematic reviews will be manually screened. Two reviewers will independently screen studies, extract data, and assess quality. Random-effect models will be employed to obtain overall pooled estimates of associations and corresponding 95% confidence intervals (CIs). This systematic review and meta-analyses will be reported following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Results will be reported as specified by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.Discussion: Findings of this review will help to clarify relationships between diabetes medication and cancer, which is critical for future efforts to improve cancer prevention. Further, challenges and limitations identified in this review will foster opportunities to refine design and analysis procedures in future studies. Systematic review registration: The systematic review protocol was registered on Open Science Framework (https://osf.io/frg5z) and on PROSPERO (registration number CRD42021239348).

show abstract

Section: Discussionmentioning

confidence: 99%

Diabetes Medication Use and Cancer Risk: Protocol for a Systematic Review

Chen¹,

Mushashi²,

Son³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In patients with DM, the production of insulin is limited and the cells do not respond adequately to the stimuli, exhibiting insulin resistance, which causes a dangerous high concentration of glucose in the blood and can trigger metabolic deficits that are harmful to health 48 . Regarding our findings from the HOMA-IR and HbA1, it has been evidenced that the results can be directly related to the genotype and daily behavioral habits.…”

Section: Discussionmentioning

confidence: 99%

Relationship between carotid intima-media thickness, physical activity, sleep quality, metabolic/inflamatory profile, body fatness, smoking and alcohol consumption in young adults

Maillane-Vanegas

Turi-Lynch

Lira

et al. 2017

Motriz: rev. educ. fis.

View full text Add to dashboard Cite

-Aim:The aim of this longitudinal study was to analyze the relationship between sleep disorder and intimamedia thickness. Method: Baseline measurements included carotid intima-media thickness, assessed by an ultrasound device; questionnaires about sleep and other behavioral variables; physical activity was measured by pedometer; body fatness was estimated by Dual-Energy X-ray Absorptiometry; fasting glucose, lipid profile and C-reactive protein were collected. Results: The occurrence rate of sleep-related disorders was 47% (95%CI= 37.2%-56.7%). Carotid intimamedia thickness was related to symptoms of insomnia (r= 0.328 [0.141 to 0.493]) and, after adjustments for potential confounders, the relationship between carotid intima-media thickness and insomnia remained statistically significant (β= 0.121 [95%CI= 0.017; 0.225]). Conclusions: In young adults, sleep disorder was significantly related to premature increase in carotid intima-media thickness.

show abstract

“…Treatment with α‐glucosidase inhibitors is usually associated with weight loss. A meta‐analysis of four RCTs did not reveal an association between α‐glucosidase inhibitors and cancer risk .…”

Section: Types Of Antidiabetes Medicationmentioning

confidence: 93%

More recent, better designed studies have weakened links between antidiabetes medications and cancer risk

Dankner

Roth

2020

Diabet. Med.

View full text Add to dashboard Cite

Background An increasing number of studies have investigated associations of antidiabetes medications with cancer risk. Antidiabetes medications are classified by their mechanisms of action on tissues and organs. They potentially act as both causative and confounding factors in the temporal association of diabetes and cancer.Aim To present the current evidence regarding both the carcinogenic and anti-carcinogenic effects of antidiabetes medications on cancer in humans.Methods A review of the scientific literature. ResultsThe most conclusive evidence shown of an association of antidiabetes medication with a specific cancer was for that of the thiazolidinedione pioglitazone with bladder cancer. Currently, there is inconclusive evidence regarding a possible association of incretin therapies, drugs of the dipeptidyl peptidase-4 inhibitor class, with the risk of pancreatic cancer. Insulin, sulfonylureas, metformin and sodium-glucose co-transporter-2 inhibitors appear not to be associated with increased risk of any cancer. Sparse evidence suggests possible protective effects against cancer incidence of metformin, sulfonylureas, thiazolidinediones, incretin-based drugs and sodium-glucose co-transporter-2 inhibitors. ConclusionThe conflicting evidence regarding associations of antidiabetes medications with cancer risk is apparently attributable to both methodological issues and to the complexity of the subject. More recent and better-designed studies have weakened the evidence for links between antidiabetes medications and cancer risk.

show abstract

Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

Cited by 27 publications

References 72 publications

Diabetes Medication Use and Cancer Risk: Protocol for a Systematic Review

Diabetes Medication Use and Cancer Risk: Protocol for a Systematic Review

Relationship between carotid intima-media thickness, physical activity, sleep quality, metabolic/inflamatory profile, body fatness, smoking and alcohol consumption in young adults

More recent, better designed studies have weakened links between antidiabetes medications and cancer risk

Contact Info

Product

Resources

About